NYSE : MRK
Merck & Co., Inc. — Key statistics
Healthcare · Drug Manufacturers - General · United States
Last price 149.52 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 368.89B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 368.89B |
| Enterprise Value | 415.66B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.47B |
| Shares Outstanding | 2.47B |
| Shares Change (YoY) | -1.77% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 81.17% |
| Float | 2.46B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 151.22 |
| Forward PE | 17.46 |
| PS Ratio | 5.47 |
| Forward PS | 5.40 |
| PB Ratio | 8.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.97 |
| P/OCF Ratio | 18.48 |
| PEG Ratio | 3.40 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 169.45 |
| EV / Sales | 6.17 |
| EV / EBITDA | 26.04 |
| EV / EBIT | 40.98 |
| EV / FCF | 25.88 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.32 |
| Quick Ratio | 0.74 |
| Debt / Equity | 1.28 |
| Debt / EBITDA | 3.29 |
| Debt / FCF | 3.36 |
| Interest Coverage | 5.17 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 6.96% |
| Return on Assets (ROA) | 11.87% |
| Return on Invested Capital (ROIC) | 5.88% |
| Return on Capital Employed (ROCE) | 23.01% |
| Weighted Average Cost of Capital (WACC) | 5.01% |
| Revenue Per Employee | $898,373 |
| Profits Per Employee | $32,707 |
| Employee Count | 75,000 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.51 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.31B |
| Effective Tax Rate | 48.57% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +72.70% |
| 50-Day Moving Average | 146.86 |
| 200-Day Moving Average | 126.71 |
| Relative Strength Index (RSI) | 56.86 |
| Average Volume (20 Days) | 10,105,458 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 26.83M |
| Short Previous Month | 34.43M |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.09% |
| Short Ratio (days to cover) | 2.68 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 67.38B |
| Gross Profit | 51.82B |
| Operating Income | 10.14B |
| Pretax Income | 4.76B |
| Net Income | 2.45B |
| EBITDA | 15.96B |
| EBIT | 10.14B |
| Earnings Per Share (EPS) | $0.99 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 7.14B |
| Total Debt | 53.91B |
| Net Cash | -46.77B |
| Net Cash Per Share | -$18.96 |
| Equity (Book Value) | 41.98B |
| Book Value Per Share | 16.99 |
| Working Capital | 8.95B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 19.97B |
| Capital Expenditures | -3.90B |
| Depreciation & Amortization | 5.82B |
| Net Borrowing | 18.69B |
| Free Cash Flow | 16.06B |
| FCF Per Share | $6.51 |
Margins
| Measure | Value |
|---|
| Gross Margin | 76.91% |
| Operating Margin | 15.05% |
| Pretax Margin | 7.07% |
| Profit Margin | 3.64% |
| EBITDA Margin | 23.69% |
| EBIT Margin | 15.05% |
| FCF Margin | 24.13% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $3.40 |
| Dividend Yield | 2.27% |
| Dividend Growth (YoY) | 4.94% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 343.87% |
| FCF Payout Ratio | 52.22% |
| Buyback Yield | 1.77% |
| Shareholder Yield | 4.04% |
| Earnings Yield | 0.66% |
| FCF Yield | 4.35% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $159.91 |
| Price Target Difference | 6.95% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 4.52% |
| EPS Growth Forecast (3Y) | 4.04% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |